MXPA05003340A - Metodo para tratamiento de pacientes con perdida masiva de sangre. - Google Patents
Metodo para tratamiento de pacientes con perdida masiva de sangre.Info
- Publication number
- MXPA05003340A MXPA05003340A MXPA05003340A MXPA05003340A MXPA05003340A MX PA05003340 A MXPA05003340 A MX PA05003340A MX PA05003340 A MXPA05003340 A MX PA05003340A MX PA05003340 A MXPA05003340 A MX PA05003340A MX PA05003340 A MXPA05003340 A MX PA05003340A
- Authority
- MX
- Mexico
- Prior art keywords
- hemoglobin
- solution
- polymerized
- molecular weight
- blood
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 72
- 210000004369 blood Anatomy 0.000 title claims abstract description 67
- 239000008280 blood Substances 0.000 title claims abstract description 67
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 272
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 272
- 241000124008 Mammalia Species 0.000 claims abstract description 12
- 210000003743 erythrocyte Anatomy 0.000 claims description 75
- 229920000642 polymer Polymers 0.000 claims description 20
- 230000036772 blood pressure Effects 0.000 claims description 12
- 231100000419 toxicity Toxicity 0.000 claims description 12
- 230000001988 toxicity Effects 0.000 claims description 12
- 208000007502 anemia Diseases 0.000 claims description 8
- 230000000747 cardiac effect Effects 0.000 claims description 8
- 238000009826 distribution Methods 0.000 claims description 8
- 206010047139 Vasoconstriction Diseases 0.000 claims description 7
- 239000000356 contaminant Substances 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 7
- 230000002496 gastric effect Effects 0.000 claims description 7
- 230000025033 vasoconstriction Effects 0.000 claims description 7
- 206010021138 Hypovolaemic shock Diseases 0.000 claims description 3
- 230000002427 irreversible effect Effects 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 206010040560 shock Diseases 0.000 claims description 3
- 230000035939 shock Effects 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 239000000243 solution Substances 0.000 description 124
- 108010034539 PolyHeme Proteins 0.000 description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 20
- 239000001301 oxygen Substances 0.000 description 20
- 229910052760 oxygen Inorganic materials 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 238000001802 infusion Methods 0.000 description 16
- 208000032843 Hemorrhage Diseases 0.000 description 14
- 208000014674 injury Diseases 0.000 description 13
- 230000008733 trauma Effects 0.000 description 13
- 230000034994 death Effects 0.000 description 12
- 231100000517 death Toxicity 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 9
- 208000034158 bleeding Diseases 0.000 description 8
- 230000000740 bleeding effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000008215 water for injection Substances 0.000 description 8
- 230000000750 progressive effect Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 108010003320 Carboxyhemoglobin Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000007477 logistic regression Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical class N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006392 deoxygenation reaction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010015719 Exsanguination Diseases 0.000 description 2
- 108010061951 Methemoglobin Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 108010002255 deoxyhemoglobin Proteins 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000011045 prefiltration Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PREOBXYMXLETCA-UHFFFAOYSA-N 2-[4-(2-carboxyphenoxy)-4-oxobutanoyl]oxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC(=O)CCC(=O)OC1=CC=CC=C1C(O)=O PREOBXYMXLETCA-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 102100037815 Fas apoptotic inhibitory molecule 3 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 101000878510 Homo sapiens Fas apoptotic inhibitory molecule 3 Proteins 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 241000219873 Vicia Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 229940021013 electrolyte solution Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- -1 iraidoesters Chemical compound 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002103 osmometry Methods 0.000 description 1
- 238000002496 oximetry Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41593502P | 2002-10-03 | 2002-10-03 | |
| PCT/US2003/031377 WO2004037279A1 (en) | 2002-10-03 | 2003-10-03 | Method for treating patients with massive blood loss |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05003340A true MXPA05003340A (es) | 2005-07-05 |
Family
ID=32176456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05003340A MXPA05003340A (es) | 2002-10-03 | 2003-10-03 | Metodo para tratamiento de pacientes con perdida masiva de sangre. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7291592B2 (https=) |
| EP (1) | EP1553968A4 (https=) |
| JP (1) | JP2006502231A (https=) |
| CN (1) | CN1703235A (https=) |
| AU (1) | AU2003272827B2 (https=) |
| CA (1) | CA2499459A1 (https=) |
| MX (1) | MXPA05003340A (https=) |
| NO (1) | NO20051390L (https=) |
| RU (1) | RU2325924C2 (https=) |
| WO (1) | WO2004037279A1 (https=) |
| ZA (1) | ZA200502307B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050049707A1 (en) * | 2003-08-29 | 2005-03-03 | Ferree Bret A. | Cemented artificial disc replacements |
| EP1471821B1 (en) * | 2002-01-15 | 2013-06-26 | Board Of Regents, The University Of Texas System | Compositions to reduce scattering of light during therapeutic and diagnostic imaging procedures |
| US20070196810A1 (en) * | 2006-01-24 | 2007-08-23 | Northfield Laboratories Inc. | Polymerized Hemoglobin Media and its Use in Isolation and Transplantation of Islet Cells |
| US20090004159A1 (en) * | 2006-01-24 | 2009-01-01 | The Board Of Trustees Of The University Of Illinoi | Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells |
| WO2008009634A2 (en) * | 2006-07-17 | 2008-01-24 | Novo Nordisk Health Care Ag | Factor viia analogues with increased activity for treating thrombocytopenia |
| RU2361608C1 (ru) * | 2008-03-18 | 2009-07-20 | Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Медбиофарм" | Кровезаменитель с функцией переноса кислорода, фармацевтическая композиция (варианты) |
| RU2452519C1 (ru) * | 2011-03-25 | 2012-06-10 | Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы | Способ компенсации глобулярного объема крови и иммуномодулирующего воздействия при трансплантации |
| CA3070172A1 (en) | 2017-07-18 | 2019-01-24 | VirTech Bio, Inc. | Blood substitutes comprising hemoglobin and methods of making |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194590A (en) * | 1986-06-20 | 1993-03-16 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| US5464814A (en) * | 1986-06-20 | 1995-11-07 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| US4826811A (en) * | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| US5955581A (en) * | 1986-11-10 | 1999-09-21 | Biopure Corporation | Method for producing a stable polymerized hemoglobin blood-substitute |
| US5854209A (en) | 1995-03-23 | 1998-12-29 | Biopure Corporation | Method for oxygenating tissue having reduced red blood cell flow |
| US5084558A (en) * | 1987-10-13 | 1992-01-28 | Biopure Corporation | Extra pure semi-synthetic blood substitute |
| US5691452A (en) * | 1995-03-23 | 1997-11-25 | Biopure Corporation | Method for preserving a hemoglobin blood substitute |
| NZ305258A (en) * | 1995-03-23 | 2000-10-27 | Biopure Corp | Stable polymerised haemoglobin blood-substitute to treat or prevent hypoxia resulting from blood loss |
| US6288027B1 (en) * | 1995-03-23 | 2001-09-11 | Biopure Corporation | Preserving a hemoglobin blood substitute with a transparent overwrap |
| US5895810A (en) * | 1995-03-23 | 1999-04-20 | Biopure Corporation | Stable polymerized hemoglobin and use thereof |
| US6271351B1 (en) * | 1995-03-23 | 2001-08-07 | Biopure Corporation | Method for preserving a hemoglobin blood substitute |
| US20020065211A1 (en) * | 1995-03-23 | 2002-05-30 | Biopure Corporation | Increasing function of organs having reduced red blood cell flow |
| US6150507A (en) * | 1995-03-23 | 2000-11-21 | Biopure Corporation | Method for producing a purified hemoglobin product |
| US5691453A (en) * | 1995-06-07 | 1997-11-25 | Biopure Corporation | Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC |
| RU2203087C2 (ru) * | 1996-03-28 | 2003-04-27 | Нортфилд Лэборэтериз, Инк. | Способ и устройство для получения бесклеточного заменителя эритроцитов |
| US5890852A (en) * | 1998-03-17 | 1999-04-06 | Emerson Electric Company | Thread cutting die and method of manufacturing same |
-
2003
- 2003-10-03 EP EP03755029A patent/EP1553968A4/en not_active Withdrawn
- 2003-10-03 CA CA002499459A patent/CA2499459A1/en not_active Abandoned
- 2003-10-03 US US10/678,927 patent/US7291592B2/en not_active Expired - Fee Related
- 2003-10-03 RU RU2005113240/14A patent/RU2325924C2/ru not_active IP Right Cessation
- 2003-10-03 JP JP2004546786A patent/JP2006502231A/ja active Pending
- 2003-10-03 AU AU2003272827A patent/AU2003272827B2/en not_active Expired - Fee Related
- 2003-10-03 WO PCT/US2003/031377 patent/WO2004037279A1/en not_active Ceased
- 2003-10-03 MX MXPA05003340A patent/MXPA05003340A/es active IP Right Grant
- 2003-10-03 CN CNA2003801009126A patent/CN1703235A/zh active Pending
-
2005
- 2005-03-16 NO NO20051390A patent/NO20051390L/no not_active Application Discontinuation
- 2005-03-18 ZA ZA2005/02307A patent/ZA200502307B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200502307B (en) | 2005-11-30 |
| US20040067876A1 (en) | 2004-04-08 |
| EP1553968A4 (en) | 2009-06-24 |
| AU2003272827A1 (en) | 2004-05-13 |
| RU2325924C2 (ru) | 2008-06-10 |
| US7291592B2 (en) | 2007-11-06 |
| NO20051390L (no) | 2005-05-30 |
| AU2003272827B2 (en) | 2009-03-19 |
| CN1703235A (zh) | 2005-11-30 |
| EP1553968A1 (en) | 2005-07-20 |
| WO2004037279A1 (en) | 2004-05-06 |
| CA2499459A1 (en) | 2004-05-06 |
| JP2006502231A (ja) | 2006-01-19 |
| RU2005113240A (ru) | 2005-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vogel et al. | Coronary constrictor effect of stroma-free hemoglobin solutions | |
| Winters | Complications of donor apheresis | |
| Johnson et al. | Resuscitation with a blood substitute abrogates pathologic postinjury neutrophil cytotoxic function | |
| Brzica et al. | Autologous blood transfusion | |
| Castro et al. | Improvement of sickle cell anemia by iron‐limited erythropoiesis | |
| MXPA05003340A (es) | Metodo para tratamiento de pacientes con perdida masiva de sangre. | |
| Keipert et al. | Pyridoxylated polyhemoglobin as a red cell substitute for resuscitation of lethal hemorrhagic shock in conscious rats | |
| IE61008B1 (en) | Composition for increasing the hematocrit of a normal mammal | |
| Bull et al. | Hypothesis: disseminated intravascular inflammation as the inflammatory counterpart to disseminated intravascular coagulation. | |
| Henry et al. | The effect of experimental hemorrhagic shock on pulmonary alveolar surfactant | |
| Brooks | Noncardiogenic pulmonary edema immediately following rapid protamine administration | |
| Przybelski et al. | A safety assessment of diaspirin cross-linked hemoglobin (DCLHb) in the treatment of hemorrhagic, hypovolemic shock | |
| COOKE et al. | Cryoprecipitate concentrates of factor VIII for surgery in hemophiliacs | |
| Shiono et al. | Application of cryoprecipitate as a hematostatic glue | |
| Chmura et al. | Perioperative use of recombinant activated factor VII in liver transplantation | |
| Jovanovic et al. | Redo cardiac surgery in a Jehovah’s Witness, the importance of a multidisciplinary approach to blood conservation | |
| HK1084875A (en) | Method for treating patients with massive blood loss | |
| Ala | Transfusion of Red Cells | |
| Pulliam | Use of blood and its components | |
| Kunz et al. | Management of severe blood loss after tumor resection in a Jehovah’s Witness | |
| Gresens et al. | Other reactions and alloimmunization | |
| WO2024086835A1 (en) | Treatment of blood transfusion-dependent patients with hematologic malignancies | |
| Spahn et al. | Augmented Acute Normovolemic Hemodilution | |
| US20240049700A1 (en) | Lipid layer preservation | |
| Dzik | Oxygen reverses deficits of cognitive function and memory and increased heart rate induced by acute severe isovolemic anemia: RB Weiskopf, J. Feiner, HW Hopf, et al. Anesthesiology 96: 871–877, 2002 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |